Sage Therapeutics Inc (NASDAQ:SAGE)’s traded shares stood at 1.1 million during the latest session, with the company’s beta value hitting 0.26. At the last check today, the stock’s price was $9.16, to imply an increase of 0.88% or $0.08 in intraday trading. The SAGE share’s 52-week high remains $13.47, putting it -47.05% down since that peak but still an impressive 49.56% since price per share fell to its 52-week low of $4.62. The company has a valuation of $573.62M, with an average of 2.03 million shares in intraday trading volume over the past 10 days and average of 1.59 million shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for Sage Therapeutics Inc (SAGE), translating to a mean rating of 2.87. Of 8 analyst(s) looking at the stock, 1 analyst(s) give SAGE a Sell rating. 0 of those analysts rate the stock as Overweight while 4 advise Hold as 3 recommend it as a Buy.
Sage Therapeutics Inc (NASDAQ:SAGE) trade information
After registering a 0.88% upside in the latest session, Sage Therapeutics Inc (SAGE) has traded red over the past five days. The 5-day price performance for the stock is -1.29%, and 40.28% over 30 days. With these gigs, the year-to-date price performance is -16.95%. Short interest in Sage Therapeutics Inc (NASDAQ:SAGE) saw shorts transact 5.25 million shares and set a 7.37 days time to cover.
The extremes give us $5 and $9 for target low and target high price respectively. As such, SAGE has been trading 1.75% off suggested target high and 45.41% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 13.20% for the past 5-year period. While 2025 is set for a 44.94% return in earnings, projections for the next 5 years are at 33.73% annually.
SAGE Dividends
Sage Therapeutics Inc has its next earnings report out on 2025-Apr-29. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Sage Therapeutics Inc (NASDAQ:SAGE)’s Major holders
Sage Therapeutics Inc insiders hold 10.41% of total outstanding shares, with institutional holders owning 83.65% of the shares at 93.36% float percentage. In total, 83.65% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 6.42 million shares (or 10.5988% of shares), all amounting to roughly $69.68 million.
The next major institution holding the largest number of shares is FMR LLC with 5.82 million shares, or about 9.6193% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $63.24 million.
